Sometimes beating earnings expectations isn't enough to save you from a rough day on Wall Street. Novo Nordisk A/S (NVO) learned that lesson Wednesday when shares tumbled despite solid fourth-quarter results, all thanks to a sobering outlook for 2026 that has investors reconsidering the weight loss drug boom.
The Danish pharmaceutical giant warned that adjusted sales growth for fiscal 2026 could fall anywhere from negative 5% to negative 13% at constant exchange rates. That's excluding revenue from the reversal of 340B provisions, which makes the picture even bleaker. The stock dropped more than 4% in premarket trading to $48.15, pushing it closer to the bottom of its 52-week range of $43.08 to $93.80.
So what's behind the gloomy forecast? A perfect storm of pricing pressure and competition. The company is grappling with lower realized prices from the "Most Favoured Nations" agreement in the U.S., patent expiry of the semaglutide molecule in certain international markets, and an increasingly crowded field of rivals chasing the massive obesity treatment opportunity.
The Numbers Tell Two Stories
Here's where things get interesting. Novo Nordisk actually delivered a strong quarter by most measures. Fourth-quarter earnings came in at 94 cents per share (6.44 Danish kroner), comfortably beating the consensus estimate of 89 cents. Revenue hit roughly $12.34 billion (79.14 billion Danish kroner), edging past expectations of $12.08 billion.
But dig deeper and you'll see the cracks forming. Sales in Q4 2025 decreased 8% measured in Danish kroner and 2% at constant exchange rates compared to the same period in 2024. The culprit? Weakness in U.S. operations, which is particularly concerning given America's importance to the obesity drug market.
The product mix reveals the shifting dynamics. GLP-1 diabetes sales dropped 5% at constant exchange rates to 37.53 billion Danish kroner, while obesity care sales increased 11% to 22.45 billion Danish kroner. Insulin sales fell 10% to 13.40 billion Danish kroner, and rare disease sales stayed flat at 5.35 billion Danish kroner.
Operating profit declined 14% to 31.74 billion Danish kroner (or 4% at constant exchange rates), squeezed by falling sales and the costs of amortizations and depreciations related to three former Catalent manufacturing sites. The operating margin compressed from 42.9% to 40.1%.
The Blockbuster Drugs
Let's talk about the stars of the show. Ozempic sales inched up just 1% to 31.83 billion Danish kroner, suggesting the diabetes blockbuster may be maturing. Meanwhile, Wegovy sales surged 17% to 21.86 billion Danish kroner as the weight loss drug continues gaining traction.
Despite the challenges ahead, CEO Mike Doustdar struck an optimistic tone about certain developments. "In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market. However, we are very encouraged by the promising early uptake from the U.S. launch of Wegovy pill, and we remain confident in our ability to drive volume growth over the coming years."
Doustdar also highlighted upcoming catalysts: "Also for this year, we look forward to regulatory decisions for next-generation treatments, such as Mim8 within haemophilia and CagriSema within obesity, as well as a number of exciting R&D read-outs, including phase 3 read-outs for etavopivat and ziltivekimab."
Pipeline Reshuffling
The company is trimming some fat from its development pipeline. Novo Nordisk terminated a phase 1 trial with an oral NRLP3 inhibitor (NN6705) and discontinued further development due to portfolio considerations. The good news is there were no safety or tolerability issues during the trial, and the company continues pursuing other preclinical NLRP3 inhibitors.
Novo Nordisk also pulled the plug on the Pumpsulin project due to portfolio considerations, though the ongoing phase 1 trial will continue to completion as planned. Additionally, the company terminated development of TMPRSS6, an RNAi in early development for rare blood disease.
On a more positive note, Novo Nordisk announced a share repurchase program for 2026 worth up to 15 billion Danish kroner, suggesting management believes the current weakness presents a buying opportunity.
The obesity drug market remains enormous, but Novo Nordisk's challenges show that even dominant players face pressure when patents expire, pricing power erodes, and competitors circle. Investors who bid these stocks to the stratosphere during the GLP-1 frenzy are now getting a reality check about what sustainable growth actually looks like.
